Seizert Capital Partners LLC Lowers Holdings in Cigna Group $CI

Seizert Capital Partners LLC reduced its stake in shares of Cigna Group (NYSE:CI) by 0.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 150,491 shares of the health services provider’s stock after selling 480 shares during the period. Cigna Group accounts for about 2.2% of Seizert Capital Partners LLC’s investment portfolio, making the stock its 15th largest position. Seizert Capital Partners LLC owned 0.06% of Cigna Group worth $49,749,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of CI. Financial Network Wealth Advisors LLC raised its stake in Cigna Group by 26.8% during the first quarter. Financial Network Wealth Advisors LLC now owns 161 shares of the health services provider’s stock worth $53,000 after purchasing an additional 34 shares during the period. Central Pacific Bank Trust Division raised its position in shares of Cigna Group by 1.0% in the 2nd quarter. Central Pacific Bank Trust Division now owns 3,440 shares of the health services provider’s stock worth $1,137,000 after buying an additional 35 shares during the period. HBK Sorce Advisory LLC boosted its holdings in Cigna Group by 3.1% in the second quarter. HBK Sorce Advisory LLC now owns 1,263 shares of the health services provider’s stock valued at $418,000 after acquiring an additional 38 shares during the last quarter. Legacy Financial Advisors Inc. grew its position in Cigna Group by 2.9% during the first quarter. Legacy Financial Advisors Inc. now owns 1,400 shares of the health services provider’s stock valued at $461,000 after acquiring an additional 39 shares during the period. Finally, Samalin Investment Counsel LLC increased its stake in Cigna Group by 2.2% during the first quarter. Samalin Investment Counsel LLC now owns 1,792 shares of the health services provider’s stock worth $590,000 after acquiring an additional 39 shares during the last quarter. 86.99% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO David Cordani bought 4,134 shares of the company’s stock in a transaction dated Monday, November 3rd. The stock was bought at an average price of $241.88 per share, with a total value of $999,931.92. Following the transaction, the chief executive officer owned 157,935 shares of the company’s stock, valued at approximately $38,201,317.80. This trade represents a 2.69% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Brian C. Evanko sold 5,368 shares of the stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $300.00, for a total transaction of $1,610,400.00. Following the transaction, the insider directly owned 51,182 shares in the company, valued at $15,354,600. The trade was a 9.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.70% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on CI shares. Cowen reaffirmed a “buy” rating on shares of Cigna Group in a research note on Tuesday, November 4th. Morgan Stanley reaffirmed an “overweight” rating and set a $355.00 price target on shares of Cigna Group in a research report on Friday, October 31st. Jefferies Financial Group reissued a “buy” rating and issued a $310.00 price objective on shares of Cigna Group in a research report on Monday, November 3rd. JPMorgan Chase & Co. cut their target price on shares of Cigna Group from $428.00 to $375.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 4th. Finally, TD Cowen lowered their price target on Cigna Group from $387.00 to $333.00 and set a “buy” rating for the company in a report on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $334.05.

Cigna Group Stock Performance

Cigna Group stock opened at $272.50 on Wednesday. Cigna Group has a 12-month low of $239.51 and a 12-month high of $350.00. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.71 and a quick ratio of 0.71. The company has a market capitalization of $72.79 billion, a price-to-earnings ratio of 14.87, a price-to-earnings-growth ratio of 0.88 and a beta of 0.44. The firm’s fifty day moving average price is $288.56 and its 200 day moving average price is $299.97.

Cigna Group (NYSE:CI) last announced its earnings results on Thursday, October 30th. The health services provider reported $7.83 earnings per share for the quarter, beating the consensus estimate of $7.64 by $0.19. Cigna Group had a return on equity of 18.80% and a net margin of 1.92%.The company had revenue of $69.57 billion during the quarter, compared to the consensus estimate of $66.40 billion. During the same period last year, the firm earned $7.51 earnings per share. The company’s revenue was up 9.5% on a year-over-year basis. Cigna Group has set its FY 2025 guidance at 29.600- EPS. On average, research analysts forecast that Cigna Group will post 29.77 EPS for the current fiscal year.

Cigna Group Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 18th. Shareholders of record on Thursday, December 4th will be issued a dividend of $1.51 per share. The ex-dividend date is Thursday, December 4th. This represents a $6.04 annualized dividend and a yield of 2.2%. Cigna Group’s payout ratio is currently 26.64%.

About Cigna Group

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.